Intellia Therapeutics, Inc. (NTLA) Research Coverage Started at Barclays PLC
Analysts at Barclays PLC started coverage on shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in a research report issued on Wednesday, Marketbeat.com reports. The brokerage set an “overweight” rating and a $29.00 price target on the stock. Barclays PLC’s target price indicates a potential upside of 30.63% from the stock’s previous close.
Several other research firms also recently weighed in on NTLA. Chardan Capital downgraded shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 price target for the company. in a research report on Tuesday, August 29th. Cann restated a “hold” rating on shares of Intellia Therapeutics in a research report on Tuesday, August 1st. Oppenheimer Holdings, Inc. began coverage on shares of Intellia Therapeutics in a research report on Tuesday, July 18th. They set a “market perform” rating for the company. Jefferies Group LLC restated a “buy” rating and set a $36.00 price target on shares of Intellia Therapeutics in a research report on Saturday, July 22nd. Finally, TheStreet upgraded shares of Intellia Therapeutics from a “d+” rating to a “c-” rating in a research report on Thursday, July 6th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Intellia Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $25.43.
Shares of Intellia Therapeutics (NASDAQ NTLA) traded up 3.02% during midday trading on Wednesday, reaching $22.20. The company’s stock had a trading volume of 204,598 shares. Intellia Therapeutics has a 12-month low of $10.83 and a 12-month high of $22.49. The stock has a 50-day moving average of $17.76 and a 200 day moving average of $15.09. The firm’s market capitalization is $801.69 million.
Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.03. Intellia Therapeutics had a negative return on equity of 22.70% and a negative net margin of 204.48%. The firm had revenue of $5.90 million during the quarter, compared to analyst estimates of $5.83 million. The company’s quarterly revenue was up 40.5% compared to the same quarter last year. Equities research analysts predict that Intellia Therapeutics will post ($1.78) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Intellia Therapeutics, Inc. (NTLA) Research Coverage Started at Barclays PLC” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/10/intellia-therapeutics-inc-ntla-research-coverage-started-at-barclays-plc.html.
In related news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the company’s stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $16.24, for a total transaction of $2,436,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 12.80% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at approximately $101,000. Nisa Investment Advisors LLC purchased a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at approximately $134,000. Bank of Montreal Can grew its stake in shares of Intellia Therapeutics by 1,031.7% in the 2nd quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock valued at $127,000 after buying an additional 7,222 shares during the period. Nationwide Fund Advisors grew its stake in shares of Intellia Therapeutics by 117.7% in the 2nd quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock valued at $129,000 after buying an additional 4,351 shares during the period. Finally, IHT Wealth Management LLC purchased a new stake in shares of Intellia Therapeutics in the 1st quarter valued at approximately $117,000. 46.52% of the stock is owned by institutional investors.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.